Kevin Tang has been appointed as the new CEO of Aurinia Pharmaceuticals on March 27, amid strong sales growth of Lupkynis, which increased by 25.5% year-over-year to reach $271.3 million in 2025. The company also issued sales guidance for 2026, projecting between $305 million and $315 million. On March 31, Kezar Life Sciences agreed to be acquired by Aurinia, with Kezar shareholders set to receive $6.95 in cash per share plus a non-transferable contingent value right. The deal is expected to close in the second quarter of 2026, and Kezar's board unanimously approved the transaction, while law firms are investigating whether the board breached fiduciary duties.
Biogen Inc. (BIIB) has officially identified Apellis Pharmaceuticals as the target of its $5.6 billion acquisition, a move aimed at strengthening its presence in immunology and rare diseases. The transaction includes the acquisition of two key drugs, EMPAVELI® and SYFOVRE®, which generated combined net sales of $689…
Read the full storyThe U.S. Food and Drug Administration (FDA) has intensified its safety warnings for Amgen's drug Tavneos, reporting dozens of severe liver injury cases and confirmed deaths. The regulator specifically highlighted vanishing bile duct syndrome as a critical risk, adding significant pressure to the biotechnology giant…
Aurinia Pharmaceuticals (AUPH) has entered into a definitive agreement to acquire Kezar Life Sciences (KZR) for $6.95 per share in cash. In addition to the cash payment, Kezar shareholders will receive one non-transferable contingent value right (CVR) tied to the clinical development of zetomipzomib and net cash…
Corcept Therapeutics (CORT) has received early approval from the U.S. Food and Drug Administration (FDA) for its oncology drug Lifyorli, targeting platinum-resistant ovarian cancer. Clinical data revealed that the drug demonstrated a significant 35% reduction in the risk of death while maintaining strong tolerability…
Alterity Therapeutics has announced a significant milestone in the clinical development of its lead drug candidate, ATH434. The company reached an agreement with the US Food and Drug Administration (FDA) regarding the design and key components of its Phase 3 development program. This alignment followed a Type C…
Biogen (BIIB) has secured an exclusive license for the ALT-B4 Hybrozyme technology from Alteogen to revolutionize its biologic drug delivery methods. The agreement focuses on developing subcutaneous formulations for two of Biogen's biologic products, moving away from traditional intravenous administration. This…